---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Limitations of current therapies"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Limitations of current therapies. Topics: Long-term prevention of attacks: Cochrane review, Attacks during prophylaxis and comparative evidence: guideline statements, Uptake of prophylaxis and cost as a barrier to access, Delayed onset of protection: pediatric guideline, and 3 further topics. 8 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Limitations of current therapies

<a id="heading-2.2.2.1.11"></a>

## 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

### Summary

- Administration frequency of first-line prophylaxis ranges from twice weekly (subcutaneous plasma-derived C1 inhibitor, every 3 or 4 days) and once daily (oral berotralstat) to every 2 weeks (lanadelumab, with every 4 weeks considered after more than 6 months of good control), monthly after a 400 mg loading dose (garadacimab), and every 4 or 8 weeks (donidalorsen). Intravenous C1 inhibitor requires venous access and has a “high cost” and “frequent administrations due to its short half-life”.
- Attacks “can still occur even in patients under LTP”. Berotralstat achieved an approximately 50% reduction in attack rate in its pivotal trial, and donidalorsen every 4 and 8 weeks reduced attacks by 81% and 55%, respectively, compared with placebo. Berotralstat, lanadelumab, and donidalorsen have a delayed onset of protection.
- In US commercial claims, 55% of patients had refill gaps, discontinued, or switched prophylaxis within a year of initiation, and on-demand treatment use “remained present for over two-thirds of patients”. A second study reported that annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaged more than $200,000 after subcutaneous prophylaxis began.
- No head-to-head trials of prophylactic agents have been published; a Cochrane review stated that this “prevented us from drawing firm conclusions on the relative efficacy of the drugs”, and indirect comparisons favor lanadelumab and C1 inhibitor over berotralstat.
- About 50% of patients receive long-term prophylaxis, even in high-income countries, and the higher costs of newer agents limit their availability.
- Second-line attenuated androgens are associated with virilization in women, dyslipidemia, and hepatotoxicity, cannot be used in pregnancy or in children and adolescents, and require semi-annual laboratory monitoring with annual liver ultrasound; tranexamic acid shows “mediocre efficacy in HAE-C1-INH”.

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf); [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf); [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf); [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf); [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

<a id="topic-2.2.2.1.11-2"></a>

### Long-term prevention of attacks: Cochrane review

> “This and the lack of head‐to‐head trials prevented us from drawing firm conclusions on the relative efficacy of the drugs.”

Source: [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

<a id="topic-2.2.2.1.11-3"></a>

### Attacks during prophylaxis and comparative evidence: guideline statements

> “Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.”
> “Although no direct comparisons between therapies have been published, indirect comparisons and a Cochrane analysis favor lanadelumab and C1-INH as LTP over berotralstat in terms of efficacy.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.11-4"></a>

### Uptake of prophylaxis and cost as a barrier to access

> “Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.”
> “Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.11-5"></a>

### Delayed onset of protection: pediatric guideline

> “Note: Berotralstat and lanadelumab have a delayed onset of a few weeks until optimal protective effect is achieved, which should be considered when initiating prophylaxis”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.11-6"></a>

### Persistence, switching, and on-demand use after starting prophylaxis: US claims

> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”
> “Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.2.1.11-7"></a>

### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.2.1.11-8"></a>

### Adherence and persistence after starting targeted prophylaxis: US linked health records and claims

> “Primary study measures were adherence, defined as the mean proportion of days covered (PDC), and persistence, defined as having no gap in treatment ≥ 45 days after the LTP initiation date.”
> “The main analysis included 357 patients (90 on berotralstat, 189 lanadelumab, and 78 SC-pdC1-INH).”
> “Adherence (mean PDC) was similar between treatments at 0.73, 0.78, and 0.74 for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.”
> “Proportions of patients persistent on index LTP after 12 months were similar across LTPs: 61%, 58%, and 53% for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.”

Source: [Zuraw et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40300843/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
